deltatrials
Completed PHASE3 NCT00000542

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Cardiovascular Diseases Coronary Disease Diabetes Mellitus Heart Diseases Heart Failure Hypercholesterolemia Hypertension Myocardial Infarction Myocardial Ischemia
Interventions Inhibitors, ACE amlodipine chlorthalidone diet, fat-restricted doxazosin lisinopril pravastatin
Updated 5 times since 2017 Last updated: Jul 28, 2016 Started: Aug 31, 1993 Primary completion: Mar 31, 2002 Completion: Mar 31, 2002

Listed as NCT00000542, this PHASE3 trial focuses on Cardiovascular Diseases and Coronary Disease and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 1993, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.